vs
Side-by-side financial comparison of Ametek (AME) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.9B, roughly 1.4× Ametek). Ametek runs the higher net margin — 20.7% vs -3.7%, a 24.4% gap on every dollar of revenue. On growth, Ametek posted the faster year-over-year revenue change (11.3% vs 9.3%). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 5.4%).
AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
AME vs BHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $2.8B |
| Net Profit | $399.4M | $-103.0M |
| Gross Margin | 37.2% | — |
| Operating Margin | 26.7% | 17.0% |
| Net Margin | 20.7% | -3.7% |
| Revenue YoY | 11.3% | 9.3% |
| Net Profit YoY | 13.5% | -205.1% |
| EPS (diluted) | $1.74 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $2.8B | ||
| Q3 25 | $1.9B | $2.7B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.7B | $2.3B | ||
| Q4 24 | $1.8B | $2.6B | ||
| Q3 24 | $1.7B | $2.5B | ||
| Q2 24 | $1.7B | $2.4B |
| Q1 26 | $399.4M | — | ||
| Q4 25 | $398.6M | $-103.0M | ||
| Q3 25 | $371.4M | $179.0M | ||
| Q2 25 | $358.4M | $148.0M | ||
| Q1 25 | $351.8M | $-58.0M | ||
| Q4 24 | $387.3M | $98.0M | ||
| Q3 24 | $340.2M | $-85.0M | ||
| Q2 24 | $337.7M | $10.0M |
| Q1 26 | 37.2% | — | ||
| Q4 25 | 36.0% | — | ||
| Q3 25 | 36.3% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.1% | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 36.0% | — |
| Q1 26 | 26.7% | — | ||
| Q4 25 | 25.3% | 17.0% | ||
| Q3 25 | 25.8% | 23.1% | ||
| Q2 25 | 26.0% | 17.5% | ||
| Q1 25 | 26.3% | 12.2% | ||
| Q4 24 | 26.6% | 21.8% | ||
| Q3 24 | 26.1% | 12.7% | ||
| Q2 24 | 25.8% | 16.2% |
| Q1 26 | 20.7% | — | ||
| Q4 25 | 19.9% | -3.7% | ||
| Q3 25 | 19.6% | 6.7% | ||
| Q2 25 | 20.2% | 5.8% | ||
| Q1 25 | 20.3% | -2.6% | ||
| Q4 24 | 22.0% | 3.8% | ||
| Q3 24 | 19.9% | -3.4% | ||
| Q2 24 | 19.5% | 0.4% |
| Q1 26 | $1.74 | — | ||
| Q4 25 | $1.73 | $-0.30 | ||
| Q3 25 | $1.60 | $0.48 | ||
| Q2 25 | $1.55 | $0.40 | ||
| Q1 25 | $1.52 | $-0.16 | ||
| Q4 24 | $1.67 | $0.24 | ||
| Q3 24 | $1.47 | $-0.23 | ||
| Q2 24 | $1.45 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $481.3M | $1.3B |
| Total DebtLower is stronger | — | $20.8B |
| Stockholders' EquityBook value | $10.9B | $-554.0M |
| Total Assets | $16.3B | $26.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $481.3M | — | ||
| Q4 25 | $458.0M | $1.3B | ||
| Q3 25 | $439.2M | $1.3B | ||
| Q2 25 | $619.7M | $1.7B | ||
| Q1 25 | $399.0M | $1.1B | ||
| Q4 24 | $374.0M | $1.2B | ||
| Q3 24 | $396.3M | $719.0M | ||
| Q2 24 | $396.6M | $595.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | $2.1B | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B |
| Q1 26 | $10.9B | — | ||
| Q4 25 | $10.6B | $-554.0M | ||
| Q3 25 | $10.5B | $-565.0M | ||
| Q2 25 | $10.4B | $-764.0M | ||
| Q1 25 | $10.0B | $-1.2B | ||
| Q4 24 | $9.7B | $-1.3B | ||
| Q3 24 | $9.6B | $-1.2B | ||
| Q2 24 | $9.3B | $-1.2B |
| Q1 26 | $16.3B | — | ||
| Q4 25 | $16.1B | $26.4B | ||
| Q3 25 | $16.2B | $26.8B | ||
| Q2 25 | $15.3B | $27.3B | ||
| Q1 25 | $14.9B | $26.4B | ||
| Q4 24 | $14.6B | $26.5B | ||
| Q3 24 | $14.8B | $26.5B | ||
| Q2 24 | $14.8B | $26.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $495.0M |
| Free Cash FlowOCF − Capex | — | $403.0M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $584.3M | $495.0M | ||
| Q3 25 | $440.9M | $405.0M | ||
| Q2 25 | $359.1M | $289.0M | ||
| Q1 25 | $417.5M | $211.0M | ||
| Q4 24 | $550.0M | $601.0M | ||
| Q3 24 | $487.2M | $405.0M | ||
| Q2 24 | $381.4M | $380.0M |
| Q1 26 | — | — | ||
| Q4 25 | $527.3M | $403.0M | ||
| Q3 25 | $420.0M | $314.0M | ||
| Q2 25 | $329.8M | $190.0M | ||
| Q1 25 | $394.5M | $96.0M | ||
| Q4 24 | $498.3M | $495.0M | ||
| Q3 24 | $460.9M | $334.0M | ||
| Q2 24 | $360.0M | $302.0M |
| Q1 26 | — | — | ||
| Q4 25 | 26.4% | 14.4% | ||
| Q3 25 | 22.2% | 11.7% | ||
| Q2 25 | 18.5% | 7.5% | ||
| Q1 25 | 22.8% | 4.2% | ||
| Q4 24 | 28.3% | 19.3% | ||
| Q3 24 | 27.0% | 13.3% | ||
| Q2 24 | 20.8% | 12.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 3.3% | ||
| Q3 25 | 1.1% | 3.4% | ||
| Q2 25 | 1.6% | 3.9% | ||
| Q1 25 | 1.3% | 5.1% | ||
| Q4 24 | 2.9% | 4.1% | ||
| Q3 24 | 1.5% | 2.8% | ||
| Q2 24 | 1.2% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | — | ||
| Q3 25 | 1.19× | 2.26× | ||
| Q2 25 | 1.00× | 1.95× | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 1.42× | 6.13× | ||
| Q3 24 | 1.43× | — | ||
| Q2 24 | 1.13× | 38.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AME
| Electronic Instruments | $1.3B | 66% |
| Electromechanical | $663.9M | 34% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
